Cytopenia clinical trials

Explore recruiting cytopenia clinical trials.

Recruiting cytopenia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cytopenia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Therapeutic effect of Hydroxychloroquine on IgA Nephropathy course QUIgAN Study

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Safety and Tolerability of REGN17235 in Adult Participants with Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome with SF3B1 Mutation

Belgium

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

The INFLUENCE Trial: Improving EveNt Free Survival by Optimizing FLUdarabine Exposure during LymphodepletioN for CAR T CEll Therapy: a randomized, multi-center study of children and young adults with B-cell acute lymphoblastic leukemia

Spain, Germany, Netherlands

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase I/II, single arm, open label study of dasatinib as toxicity prophylaxis in the context of therapy with idecabtagene vicleucel in relapsed/refractory multiple myeloma

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

GFM-ONUVEN-MDS : A phase I/II, open-label, single arm, multicenter dose-finding study to assess the safety and preliminary efficacy of Oral Azacitidine CC-486 (ONUREG®) in combination with Venetoclax (VENCLYXTO®) in previously untreated higher-risk myelodysplastic syndromes ineligible for allogenic transplantation

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Repurposing Metformin as a Leukemia-preventive Drug in CCUS and LR-MDS

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Cytopenia trials by city

Cytopenia in Toronto Cytopenia in Vancouver Cytopenia in Montreal Cytopenia in Calgary Cytopenia in Edmonton Cytopenia in Ottawa Cytopenia in Winnipeg Cytopenia in Quebec City Cytopenia in Hamilton Cytopenia in Kitchener Cytopenia in London Cytopenia in Halifax Cytopenia in New York Cytopenia in Los Angeles Cytopenia in Chicago Cytopenia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease